{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:15:06Z","timestamp":1788077706922,"version":"build-2784847793"},"reference-count":36,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background: Advanced glycation end products (AGEs) and their receptor receptor for AGEs (RAGE) promote tumor progression via activation of the nuclear factor-kappa B (NF-?B) signaling pathway. Although 3-Hydroxyflavone exhibits anticancer properties, its role in oral squamous cell carcinoma (OSCC) and its interaction with the AGEs\/RAGE\/NF-?B axis remain unclear. Objectives: This study investigated whether 3-Hydroxyflavone inhibits OSCC by modulating miR-142-5p within the AGEs\/RAGE\/NF-?B axis. Methods: The expression of p65 and miR-142-5p was analyzed in both OSCC tissues and Tca8113 cells. TargetScan prediction and dual-luciferase reporter assays confirmed that p65 is a direct target of miR-142-5p. The effects of 3-Hydroxyflavone on OSCC cells were evaluated using MTT and colony formation assays. Additionally, immunohistochemistry was performed to assess p65 expression in tumor tissues, and Kaplan-Meier analysis was used to evaluate patient survival. Results: OSCC tissues showed increased p65 nuclear translocation and decreased miR-142-5p levels. The miR-142-5p directly inhibited p65. The 3-Hydroxyflavone treatment suppressed OSCC cell proliferation and colony formation by upregulating miR-142-5p and inhibiting the AGEs\/RAGE\/NF-?B pathway. High p65 expression correlated with poor survival, while 3-Hydroxyflavone treatment reduced p65 and improved survival. Conclusion: The 3-Hydroxyflavone inhibits OSCC proliferation and enhances survival by upregulating miR-142-5p, which suppresses AGEs\/RAGE\/NF-?B signaling, suggesting a novel therapeutic strategy.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.9.261.1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:56:48Z","timestamp":1782633408000},"source":"Crossref","is-referenced-by-count":0,"title":["3-Hydroxyflavone inhibits the cytotoxicity of oral squamous cell carcinoma cells through the AGEs\/RAGE\/NF-?B signaling pathway"],"prefix":"10.36721","author":[{"given":"Yuan","family":"Cong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Ai Y, Liu S, Luo H, Wu S, Wei H, Tang Z, Li X, Lv X and  Zou C (2021). METTL3 intensifies the progress of oral squamous cell carcinoma via modulating the m6A amount of PRMT5 and PD-L1. J Immunol Res., 2021:6149558.","DOI":"10.1155\/2021\/6149558"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ayoolu OS, Ogbole OO, Ajaiyeoba EO, Nchiozem-Ngnitedem VA, Demissie TB, Elbadawi M, Efferth T, Bedane KG and Spiteller M (2022). Flavanols from Tetrapleura tetraptera with cytotoxic activities. Fitoterapia., 160: 105206.","DOI":"10.1016\/j.fitote.2022.105206"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bao Y, Zhai J, Chen H, Wong CC, Liang C, Ding Y, Huang D, Gou H, Chen D, Pan Y, Kang W, To KF and Yu J (2023). Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut., 72(8): 1497\u20131509.","DOI":"10.1136\/gutjnl-2022-328845"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Cheng L, Tang Z, Li M and Huang C (2026). Hyperoside ameliorates lupus nephritis by suppressing AKT1-mediated PANoptosis in podocytes: Integrating network pharmacology and experimental validation. Front Pharmacol., 16: 1726254.","DOI":"10.3389\/fphar.2025.1726254"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Contrera KJ, Kansara S, Goyal N, Mady LJ, Puram SV, Young GD, Zandberg DP, Uppaluri R, Ferrarotto R, Holsinger FC, Ferris RL, Wenig BL and Curry JM (2025). Neoadjuvant therapy for mucosal head and neck squamous cell carcinoma: A review from the American head and neck society. JAMA Otolaryngol Head Neck Surg., 151(6): 615\u2013625.","DOI":"10.1001\/jamaoto.2025.0410"},{"key":"ref5","unstructured":"Dai J, Wei H, Yang G and Zhao B (2025). miR-142-5p affects oral squamous cell carcinoma by regulating PIAS3\/pSTAT3. Ann Clin Lab Sci., 55(2): 179\u2013184."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dong H, Zhang Y, Huang Y and Deng H (2022). Pathophysiology of RAGE in inflammatory diseases. Front Immunol., 13: 931473.","DOI":"10.3389\/fimmu.2022.931473"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Feng J, Li S, Zhang B, Duan N, Zhou R, Yan S, Elango J, Liu N and Wu W (2022). FGFC1 exhibits anti-cancer activity via inhibiting NF-\u03baB signaling pathway in EGFR-Mutant NSCLC cells. Mar Drugs., 20(1): 76.","DOI":"10.3390\/md20010076"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gan X, Shu Z, Wang X, Yan D, Li J, Ofaim S, Albert R, Li X, Liu B, Zhou X and Barabasi AL (2023). Network medicine framework reveals generic herb-symptom effectiveness of traditional Chinese medicine. Sci Adv., 9(43): eadh0215.","DOI":"10.1126\/sciadv.adh0215"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Hong SH, Kang N, Kim O, Hong SA, Park J, Kim J, Lee MA and Kang J (2022). EGFR-tyrosine kinase inhibitors induced activation of the autocrine CXCL10\/CXCR3 pathway through crosstalk between the tumor and the microenvironment in EGFR-mutant lung cancer. Cancers (Basel)., 15(1): 124.","DOI":"10.3390\/cancers15010124"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Keam B, Machiels JP, Kim HR, Licitra L, Golusinski W, Gregoire V, Lee YG, Belka C, Guo Y, Rajappa SJ, Tahara M, Azrif M, Ang MK, Yang MH, Wang CH, Ng QS, Wan Zamaniah WI, Kiyota N, Babu S, Yang K and Pentheroudakis G (2021). Pan-asian adaptation of the EHNS-ESMO-ESTRO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ESMO Open., 6(6): 100309.","DOI":"10.1016\/j.esmoop.2021.100309"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Khoo SH, Wu PR, Yeh KT, Hsu SL and Wu CH (2023). Biological and clinical significance of the AGE-RAGE axis in the aggressiveness and prognosis of prostate cancer. J Food Drug Anal., 31(4): 664\u2013682.","DOI":"10.38212\/2224-6614.3475"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Koushki M, Amiri-Dashatan N, Rezaei-Tavirani M, Robati RM, Fateminasab F, Rahimi S, Razzaghi Z and Farahani M (2024). Screening the critical protein subnetwork to delineate potential mechanisms and protective agents associated with arsenic-induced cutaneous squamous cell carcinoma: A toxicogenomic study. Food Chem Toxicol., 185: 114451.","DOI":"10.1016\/j.fct.2024.114451"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Li X, Wang G, Sun X, Feng Y, Wang L, Sun G and Qiao H (2023). Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer. Cell Mol Biol (Noisy-le-grand)., 69(14): 155\u2013160.","DOI":"10.14715\/cmb\/2023.69.14.25"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Li X, Su Y, Li N, Zhang FR and Zhang N (2021). Berberine attenuates MPP+-induced neuronal injury by regulating LINC00943\/miR-142-5p\/KPNA4\/NF-\u03baB pathway in SK-N-SH cells. Neurochem Res., 46(12): 3286\u20133300.","DOI":"10.1007\/s11064-021-03431-w"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Li Z (2022). Overexpression of lncRNA HOXA-AS2 promotes the progression of oral squamous cell carcinoma by mediating SNX5 expression. BMC Mol Cell Biol., 23(1):59.","DOI":"10.1186\/s12860-022-00457-y"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Lin W, Luo Y, Wu J, Zhang H, Jin G, Guo C, Zhou H, Liang H and Xu X (2023). Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment. J Immunother Cancer., 11(11): e007402.","DOI":"10.1136\/jitc-2023-007402"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Lin Z, Chen M, Wan Y, Lei L and Ruan H (2020). miR-574-5p targets FOXN3 to regulate the invasion of nasopharyngeal carcinoma cells via Wnt\/\u03b2-Catenin pathway. Technol Cancer Res Treat., 19: 1533033820971659.","DOI":"10.1177\/1533033820971659"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang J, Weng D and Xie Y (2024). A1CF binding to the p65 interaction site on NKRF decreased IFN-\u03b2 expression and p65 phosphorylation (Ser536) in renal carcinoma cells. Int J Mol Sci., 25(7): 3576.","DOI":"10.3390\/ijms25073576"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Pai S, Yadav VK, Kuo KT, Pikatan NW, Lin CS, Chien MH, Lee WH, Hsiao M, Chiu SC, Yeh CT and Tsai JT (2021).  PDK1 inhibitor BX795 improves cisplatin and radio-efficacy in oral squamous cell carcinoma by downregulating the PDK1\/CD47\/Akt-mediated glycolysis signaling pathway. Int J Mol Sci., 22(21):11492.","DOI":"10.3390\/ijms222111492"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Pan S, Guan Y, Ma Y, Cui Q, Tang Z, Li J, Zu C, Zhang Y, Zhu L, Jiang J and Liu Z (2022). Advanced glycation end products correlate with breast cancer metastasis by activating RAGE\/TLR4 signaling. BMJ Open Diabetes Res Care., 10(2): e002697.","DOI":"10.1136\/bmjdrc-2021-002697"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Rajesh RU and Sangeetha D (2024). Therapeutic potentials and targeting strategies of quercetin on cancer cells: Challenges and future prospects. Phytomedicine., 133: 155902.","DOI":"10.1016\/j.phymed.2024.155902"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Rojas A, Lindner C, Schneider I, Gonzalez I and Morales MA (2023). Contributions of the receptor for advanced glycation end products axis activation in gastric cancer. World J Gastroenterol., 29(6): 997\u20131010.","DOI":"10.3748\/wjg.v29.i6.997"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Senavirathna L, Pan S and Chen R (2023). Protein advanced glycation end products and their implications in pancreatic cancer. Cancer Prev Res (Phila)., 16(11): 601\u2013610.","DOI":"10.1158\/1940-6207.CAPR-23-0162"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Shan F, Shen S, Wang X and Chen G (2023). BST2 regulated by the transcription factor STAT1 can promote metastasis, invasion and proliferation of oral squamous cell carcinoma via the AKT\/ERK1\/2 signaling pathway. Int J Oncol., 62(4):54.","DOI":"10.3892\/ijo.2023.5502"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Shan W, Li G, Zhang H, Zhang R, Liu J, Gao L, Li Y, Fan L, Yang C and Liu J (2025). TAP1 promotes immune escape by activating JNK\/STAT1\/PD-L1 signaling in EBV-associated gastric cancer. Mol Cell Biochem., 480(10): 5429\u20135446.","DOI":"10.1007\/s11010-025-05319-7"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Sharen G, Cheng H, Hu X, Miao J and Zhao D (2022). M1-like tumor-associated macrophages enhance proliferation and anti-apoptotic ability of liver cancer cells via activating the NF-\u03baB signaling pathway. Mol Med Rep., 26(5): 331.","DOI":"10.3892\/mmr.2022.12847"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Shen P, Lin W, Deng X, Ba X, Han L, Chen Z, Qin K, Huang Y and Tu S (2021). Potential implications of quercetin in autoimmune diseases. Front Immunol., 12: 689044.","DOI":"10.3389\/fimmu.2021.689044"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, Nice EC, Tang J and Huang C (2023). Oral squamous cell carcinomas: State of the field and emerging directions. Int J Oral Sci., 15(1): 44.","DOI":"10.1038\/s41368-023-00249-w"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Tarle M and Luksic I (2024). Pathogenesis and therapy of oral carcinogenesis. Int J Mol Sci., 25(12): 6343.","DOI":"10.3390\/ijms25126343"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Xu B, Peng YJ and Zhu WJ (2022). Curcumin inhibits viability of clear cell renal cell carcinoma by down-regulating ADAMTS18 gene methylation though NF-\u03ba B and AKT signaling pathway. Chin J Integr Med., 28(5): 419\u2013424.","DOI":"10.1007\/s11655-021-3445-z"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Xu JZ, An Y, Sun JX, Xiong YF, Liu CQ, Zhang SH, Xia ZY, Hu J, Zhang ZY, Guo CX, Liu BL, Guan W, Wang SG and Xia QD (2026). Oncolytic virus OH2 induces PD-L1 upregulation via NF-\u03baB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system. J Immunother Cancer., 14(2): e013818.","DOI":"10.1136\/jitc-2025-013818"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Zareifar P, Ahmed HM, Ghaderi P, Farahmand Y, Rahnama N, Esbati R, Moradi A, Yazdani O and Sadeghipour Y (2024). miR-142-3p\/5p role in cancer: From epigenetic regulation to immunomodulation. Cell Biochem Funct., 42(2): e3931.","DOI":"10.1002\/cbf.3931"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Zhao W, Zheng XD, Tang PY, Li HM, Liu X, Zhong JJ and Tang YJ (2023). Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi-active components combination. Med Res Rev., 43(5): 1778\u20131808.","DOI":"10.1002\/med.21963"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu C, Jin S, Xie L, Xiao Q and Yao J (2025). Ultrasound-targeted nanobubbles codelivering NKP-1339 and miR-142-5p for synergistic mitochondrial immunogenic cell death and PD-L1 inhibition in cancer therapy. Biomater Res., 29: 0232.","DOI":"10.34133\/bmr.0232"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Zou C, Lv X, Wei H, Wu S, Song J, Tang Z, Liu S, Li X and  Ai Y (2022).  Long non-coding RNA LINC00472 inhibits oral squamous cell carcinoma via miR-4311\/GNG7 axis. Bioengineered., 13(3):6371-6382.","DOI":"10.1080\/21655979.2022.2040768"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:01:18Z","timestamp":1788076878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":36,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.9.261.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}